Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

Article

Pfizer Inc. today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Hospira.

Pfizer Inc. today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira. The FTC’s clearance is contingent upon Pfizer’s commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.

In addition, Pfizer announced that Brazil’s Superintendency-General of CADE has published its unconditional clearance decision.

“We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira,” said Ian Read, Chairman and Chief Executive Officer, Pfizer. “We now look forward to combining our two companies and expect the transaction to close in early September.”

Related Videos
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Opill manufacturing | Perrigo
Healthy food selection - Image credit: Alexander Raths | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.